ECX + Panitumumab vs. ECX Alone in Locally Advanced Gastric Cancer or Cancer of the Gastroesophageal Junction
That panitumumab in combination with Epirubicin, Cisplatin and Capecitabine (ECX) will safely decrease the frequency of pT3/T4 below that of ECX alone in subjects with locally advanced adenocarcinoma of the stomach and gastroesophageal junction.
Stomach Neoplasms|Gastroesophageal Junction Neoplasms
DRUG: Epirubicin, Cisplatin, Capecitabine, Panitumumab|DRUG: Epirubicin, Cisplatin, Capecitabine
Frequency of pT3/T4 categories after surgery, after 9 weeks treatment
Frequencies of pN2/N3 categories after surgery, After 9 weeks treatment
That panitumumab in combination with Epirubicin, Cisplatin and Capecitabine (ECX) will safely decrease the frequency of pT3/T4 below that of ECX alone in subjects with locally advanced adenocarcinoma of the stomach and gastroesophageal junction.